Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
NORFLOXACIN PRIMARY PROPHYLAXIS OF BACTERIAL-INFECTIONS IN CIRRHOTIC-PATIENTS WITH ASCITES - A DOUBLE-BLIND RANDOMIZED TRIAL
Autore:
GRANGE JD; ROULOT D; PELLETIER G; PARIENTE EA; DENIS J; INK O; BLANC P; RICHARDET JP; VINEL JP; DELISLE F; FISCHER D; FLAHAULT A; AMIOT X;
Indirizzi:
HOP TENON,SERV HEPATOL,4 RUE CHINE F-75020 PARIS FRANCE HOP AVICENNE F-93009 BOBIGNY FRANCE HOP BICETRE LE KREMLIN BICETR FRANCE CHR PAU PAU FRANCE CHR CORBEIL CORBEIL ESSONNES FRANCE CHR SOISSONS SOISSONS FRANCE HOP JEAN VERDIER BONDY FRANCE HOP ST ELOI MONTPELLIER FRANCE HOP PURPAN TOULOUSE FRANCE CHR EVRY EVRY FRANCE HOP TENON,SERV BACTERIOL PARIS FRANCE
Titolo Testata:
Journal of hepatology
fascicolo: 3, volume: 29, anno: 1998,
pagine: 430 - 436
SICI:
0168-8278(1998)29:3<430:NPPOBI>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLACEBO-CONTROLLED TRIAL; FLUID CULTURE TECHNIQUE; MESENTERIC LYMPH-NODES; PROTEIN-CONCENTRATION; PREDICTIVE FACTORS; FIRST EPISODE; PERITONITIS; PREVENTION; ANTIBIOTICS; DECONTAMINATION;
Keywords:
GRAM-NEGATIVE BACILLI; NORFLOXACIN; PRIMARY PROPHYLAXIS; SEVERE INFECTION; SPONTANEOUS BACTERIAL PERITONITIS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
34
Recensione:
Indirizzi per estratti:
Citazione:
J.D. Grange et al., "NORFLOXACIN PRIMARY PROPHYLAXIS OF BACTERIAL-INFECTIONS IN CIRRHOTIC-PATIENTS WITH ASCITES - A DOUBLE-BLIND RANDOMIZED TRIAL", Journal of hepatology, 29(3), 1998, pp. 430-436

Abstract

Backgrounds/Aims: Norfloxacin is useful to prevent infections in hospitalized cirrhotic patients with low ascitic fluid protein concentrations. It is also effective in preventing the recurrence of spontaneous bacterial peritonitis. The aim of our study was to determine the efficacy of norfloxacin in the primary prophylaxis of gram-negative bacilliinfections in cirrhotic patients with low ascitic fluid protein levels (<15 g/l), Methods: One hundred and seven patients mere randomized to receive norfloxacin (400 mg/day; n=53) or placebo (n=54) for 6 months. The patients had no history of infection since cirrhosis diagnosis and no active infection. Results: The probability of gram-negative infection was significantly lon er among patients treated with norfloxacin than among those treated with placebo. Six gram-negative bacilli infections occurred in the placebo group and none in the treatment group. Severe infections (spontaneous bacterial peritonitis, neutrocytic ascites and bacteremia) developed in nine patients in the placebo group (17%) and in one patient in the norfloxacin group (2%; p<0.03), There was no between-group difference in the overall rate of infection or in survival, In ten patients from the norfloxacin group, gram-negative bacilli not present in baseline stool cultures were transiently isolatedin follow-up cultures. Conclusions: These data show that primary prophylaxis with norfloxacin for 6 months is effective in the prevention of infections caused by gram-negative bacilli in cirrhotic patients with low ascitic fluid total protein levels.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 22:44:37